Shots:
- The approvals are based on the clinical trials to evaluate mepolizumab vs PBO when added to SoC in patients with HES, EGPA & CRSwNP
- In HES, patients experienced a HES flare (28% vs 56%) @ 32wks. The therapy increased both accrued time in remission & the proportion of patients who achieved remission in patients with EGPA while 70% of patients had a diagnosis of asthma, improvements in the size of nasal polyps @52wks. & in nasal obstruction @49-52wks. along with a reduction in further surgeries @52wks. in patients with CRSwNP
- Nucala is the 1st anti-IL-5 biologic treatment for HES or CRS with nasal polyps in the EU & is available as a solution in a prefilled pen or syringe or as a powder
Click here to read full press release/ article | Ref: GSK | Image: Economictimes
The post GSK’s Nucala (mepolizumab) Receives the EC’s Approval for the Treatment of Eosinophil-Driven Diseases first appeared on PharmaShots.
